论文部分内容阅读
目的研究拉米夫定治疗小儿慢性乙型肝炎(乙肝)的临床效果和价值。方法 60例小儿慢性乙肝患儿作为研究对象,随机分为对照组和实验组,对照组30例患儿接受常规的治疗方法 ,实验组30例患儿则接受拉米夫定治疗。两组患儿均连续治疗10个月,对两组患儿在临床体征表现的疗效和安全性方面进行比较。结果相比于对照组,实验组患儿10个月后的治疗效果明显更好,组间差异具有统计学意义(P<0.05),治疗后两组患儿的不良反应情况组间比较差异无统计学意义(P>0.05)。结论拉米夫定用于治疗小儿慢性乙型肝炎疗效显著,小儿后期体征反映较好,不良反应症状表现不明显,临床价值较高,值得推广。
Objective To study the clinical efficacy and value of lamivudine in treating children with chronic hepatitis B (hepatitis B). Methods Sixty children with chronic hepatitis B from our hospital were randomly divided into control group and experimental group. Thirty children in control group received routine treatment, and 30 patients in experimental group received lamivudine treatment. The two groups of children were treated for 10 consecutive months, the two groups of children in clinical signs and signs of the efficacy and safety were compared. Results Compared with the control group, the experimental group 10 months after treatment, the treatment effect was significantly better, the difference between the two groups was statistically significant (P <0.05), two groups of children after treatment of adverse reactions were no significant difference between groups Statistical significance (P> 0.05). Conclusions Lamivudine is effective in treating chronic hepatitis B in children. It has a good clinical manifestations in late pediatric patients. The symptoms of adverse reactions are not obvious and its clinical value is high. It is worth to be popularized.